Blood mean platelet volume and platelet lymphocyte ratio as new predictors of hip osteoarthritis severity

Özlem Taşoğlu, MD, Specialist*a, Ali Şahin, MD, Specialist*b, Gülşah Karataş, MD, Specialist*b, Engin Koyuncu, MD, Specialist*b, İrfan Taşoğlu, MD, Associate professor*c, Osman Tecimen, MD, Associate professorb, Neşe Özgirgin, MD, Associate professora

Abstract
Osteoarthritis (OA) is a low grade systemic inflammatory disease in which many inflammatory mediators are known to be elevated in the periphereic blood. Blood platelet lymphocyte ratio (PLR) and mean platelet volume (MPV) are accepted as novel markers in many of the systemic inflammatory disorders, but have not been investigated in synovitis-free radiographic OA yet.

The aim of this study was to evaluate the levels of blood PLR and MPV in radiographic hip OA. A total of 880 patients were evaluated retrospectively and after certain exclusion criteria, 237 of them who have primary hip OA were included. Age, sex, height, weight, body mass index, neutrophil, lymphocyte and platelet counts, erythrocyte sedimentation rate (ESR), PLR, and MPV levels were recorded, Kellgren–Lawrence (KL) grading of the hip joints were performed. Patients were then divided into 2 groups as KL grades 1 to 2 (mild–moderate) and KL grades 3 to 4 (severe) hip OA.

Mean age, mean neutrophil, lymphocyte and platelet counts, mean MPV, mean PLR, and mean ESR were statistically significantly different between mild/moderate hip OA group and severe hip OA group. In univariate analysis, older age and higher MPV, PLR, and ESR were severely associated with severe hip OA. In multiple logistic regression analysis, MPV, PLR, and ESR emerged as independent predictors of severe hip OA.

The results of the present study, for the first time in the literature, suggest blood PLR and MPV as novel inflammatory markers predicting the radiographic severity of hip OA in the daily practice.

Abbreviations: AS = ankylosing spondylitis, BMI = body mass indexes, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, KL = Kellgren–Lawrence, MPV = mean platelet volume, OA = osteoarthritis, PLR = platelet–lymphocyte ratio, RA = rheumatoid arthritis, SLE = systemic lupus erythematosus.

Keywords: coxarthrosis, inflammation, mean platelet volume, platelet lymphocyte ratio, risk factors

1. Introduction

Osteoarthritis (OA) is one of the most common joint diseases and cause of disability especially in the elderly. Although formerly known as a mechanically activated wear of the cartilage tissue, OA is now known as a low grade inflammatory disease of the entire joint affecting not only the cartilage but also the synovium, synovial fluid, subchondral bone, and adjacent muscles.[1,2] Hip OA is one of the most common forms of OA. Unlike knee OA, mechanical overload is not at the forefront in the pathogenesis. High body mass index or occupations involving regular heavy lifting have a lower level of evidence in the pathogenesis of hip OA compared to knee OA.[3] As mechanical stress and inflammatory response acts simultaneously in OA progression; lower level of evidence about mechanical stress seems to underscore inflammatory mechanisms.

The inflammatory and anti-inflammatory mediators that are known to play a role in OA pathogenesis are, IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-11, IL-13, IL-15, IL-17, TNF-α, leukocyte inhibitory factor, IL-1 receptor antagonist, matrix metalloproteinases, proteases, chemokines, nitric oxide, and prostoglandins and leukotriens. These mediators are mainly synthesized by synoviocytes and chondrocytes of the affected joints and disperse into the synovial fluid.[4–7] It is also known that IL-1, IL-6, IL-15, and TNF-α can also be found in the serum of patients with OA.[8,9] Several inflammatory mediators, especially IL-6 is known to stimulate platelet production from megakaryocytes.[10] Moreover, platelet activation and longer platelet survival also takes place giving way to leukocyte activation and vice versa. On the basis of the above mentioned inflammatory state, platelet count in peripheral blood increases.[11–14]

It is known that increased platelet–lymphocyte ratio (PLR) is related to disease activity and severity in rheumatoid arthritis (RA),[15,16] psoriasis, psoriatic arthritis.[17] Moreover, it is also known that alterations of mean platelet volume (MPV) can also be used as an indicator of disease severity in many of the systemic
inflammatory diseases like RA, ankylosing spondylitis (AS), psoriatic arthritis, . . . etc.[18–29] Nevertheless, MPV and PLR as a marker of OA severity has not been studied in the literature before. So the aim of the present study is to investigate serum MPV and PLR as useful markers demonstrating the severity of hip OA.

2. Patients and methods

Eight hundred eighty consecutive outpatients who were admitted to physical medicine and rehabilitation department of Ankara Physical Medicine and Rehabilitation Education and Research Hospital and orthopedic department of Ankara Ataturk Education and Research Hospital with a preliminary diagnosis of hip OA between January 2014 and January 2016 were evaluated retrospectively. Hospital ethics committee approval was obtained from Atatürk Education and Research Hospital Ethics Committee.

According to the medical records 643 patients were excluded from the study; 433 patients with referring pain unrelated to hip pathology, 80 patients with developmental dysplasia of the hip, 26 patients with a history of avascular necrosis of the hip, 25 patients with high levels of infection tests (white blood cell, sedimentation, C-reactive protein), 18 patients with accompanying rheumatologic disease, 18 patients with a history of avascular necrosis of the hip, 10 patients with trochanteric bursitis, 4 patients with a diagnosis of tumor lesion of the hip, 3 patients with a history of hip fracture, 2 patients with a history of traumatic dislocation of the hip, 2 patients with inguinal lymphadenopathy, 2 patients with a history of lumbar stabilization operation, 2 patients with a history of hemiplegia, 2 patients with a diagnosis fibromyalgia, 1 patient with scoliosis, 3 patients with a history of cardiac disease, 1 patient with Wilson disease, 1 patient with hyperparathyroidism. Finally a total of 237 patients (167 females, 70 males) with a diagnosis of primary OA of the hip were included into the study. Age, sex, height, and weight of the patients were recorded. Body mass indexes (BMI) were calculated. Kellgren–Lawrence (KL) grading of the mostly affected hip joint was performed for each patient through the evaluation of X-ray images. Neutrophil, lymphocyte and platelet counts, MPV, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) values of each patient obtained at the same time with the X-ray images were recorded. Blood PLR levels were calculated. For missing information, patient interviews were carried out by telephone calls. Patients were then divided into 2 groups as patients with KL grades 1–2 (mild/moderate) hip OA and patients with KL grades 3–4 (severe) hip OA.[30]

The KL grading was used for classifying OA according to radiographic signs. Four different radiographic features: joint space narrowing, osteophytes, subchondral sclerosis, and subchondral cysts are evaluated and X-rays are graded from 1 to 4. Higher grades are associated with more severe OA.[31] Although it was firstly developed for knee joint, KL grading can also be used for most of the joints including hip.[30,32] KL grading of both knees were usually the same but, if obvious difference was present between knees, the most severely affected knee’s grading was recorded as a single score.

2.1. Statistical analysis

Analyses were performed using SPSS. Continuous data were presented as mean ± SD. Categorical variables were summarized as percentages. Comparisons between groups were made using Chi-square tests for categorical variables, independent samples Student t tests for normally distributed continuous variables and Mann–Whitney U tests when the distribution was skewed. A P-value <0.05 was considered statistically significant.

Effects of different variables on severe knee OA were calculated in univariate analysis for each. Variables, for which the unadjusted P-value was <0.10 in logistic regression analysis, were identified as potential risk markers and included in the full model. We reduced the model using stepwise multivariate logistic regression analysis and eliminated potential markers using likelihood ratio tests. A P-value <0.05 was considered statistically significant, and the confidence interval was 95%.

3. Results

Of the 237 patients, 167 (70.46%) were females and 70 (29.54%) were males. Mean age was 62.09 ± 11.18 years and mean BMI was 28.64 ± 7.1 kg/m². Demographic and laboratory parameters of the patients according to hip OA severity (mild/moderate OA, KL grades 1–2 vs severe OA, KL grades 3–4) are presented in Table 1.

Mean age (P < 0.001), mean neutrophil (P = 0.02), lymphocyte (P = 0.04) and platelet (P = 0.03) counts, mean MPV (P < 0.001), mean PLR (P < 0.001), and mean ESR (P < 0.01) were statistically significantly different between mild/moderate hip OA group and severe hip OA group (Table 1). Mean BMI and mean CRP were similar in both groups (Table 1).

In univariate analysis; older age (P < 0.001), higher MPV (P < 0.001), higher PLR (P < 0.001), and higher ESR (P < 0.001) were severely associated with severe hip OA. In multiple logistic regression analysis, MPV (P < 0.001), PLR (P < 0.001), and ESR

---

**Table 1**

| Demographic and clinical characteristics and laboratory findings of hip osteoarthritis patients according to hip osteoarthritis severity. |
|---------------------------------------------------------------|
| All patients (n = 237) | KL grade 1–2 (n = 136) | KL grade 3–4 (n = 101) | P       |
|---------------------|---------------------|---------------------|--------|
| Gender (%female)    | 70.46               | 74.26               | 65.34  | 0.13   |
| Age                 | 62.09 ± 11.18       | 56.22 ± 11.53       | 65.55 ± 9.45 | < 0.001 |
| BMI                 | 28.64 ± 7.1         | 28.1 ± 4.5          | 29.23 ± 6.2 | 0.62   |
| Neutrophil count    | 4.11 ± 1.28         | 3.94 ± 1.22         | 4.33 ± 3.2 | 0.02   |
| Lymphocyte count    | 2.29 ± 0.70         | 2.36 ± 0.70         | 2.18 ± 0.68 | 0.04   |
| Platelet count      | 247.98 ± 67.42      | 239.86 ± 53.30      | 259.18 ± 71.39 | 0.03   |
| MPV                 | 9.88 ± 1.32         | 9.42 ± 1.31         | 10.49 ± 1.06 | < 0.001 |
| PLR                 | 116.29 ± 41.03      | 107.42 ± 35.19      | 128.24 ± 45.25 | < 0.001 |
| ESR                 | 17.50 ± 16.40       | 11.41 ± 10.47       | 25.54 ± 19.18 | < 0.01 |
| CRP                 | 5.16 ± 2.53         | 4.95 ± 2.14         | 5.40 ± 2.93 | 0.19   |

BMI = body mass index, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, KL = Kellgren–Lawrence, MPV = mean platelet volume, PLR = platelet-lymphocyte ratio.
(P < 0.001) emerged as independent predictors of severe OA of the hip (Table 2).

### 4. Discussion

According to the results of the present study, patients with severe hip OA have elevated blood PLR and MPV levels compared to patients with mild/moderate hip OA and high PLR and MPV are independent predictors of hip OA severity. To our knowledge, this study is the first one demonstrating PLR and MPV, 2 basic, inexpensive and easily available blood tests, can be used as markers to assess the radiographic severity of OA of the hip in the daily practice.

In the literature there is some evidence for elevated ESR in OA patients. Hanada et al. [33] found elevated levels of ESR in knee OA patients and moreover ESR levels of patients with KL grade 3 and 4 knee OA were higher than patients with KL grade 1 knee OA. In another study by Sanchez-Ramirez et al., elevated levels of serum ESR have been found to be associated with lower quadriceps and hamstring muscles strength. Their study also demonstrated the association of elevated ESR and OA severity, but in an indirect way, as the muscle weakness and knee OA severity are directly associated. [34] Our results are also in accordance with the literature, with elevated PLR levels in severe hip OA group.

Recently, increased PLR was found to be directly associated with disease activity in RA [35, 36] and disease severity in psoriasis [37] and was also found to be a strong predictor of psoriatic arthritis in psoriasis patients. Apart from rheumatologic diseases, higher levels of PLR, as a marker of systemic inflammation, seems to be associated with reduced survival in gastric, colorectal, and pancreatic cancers [38–39] and poor prognosis in vascular surgery. [40, 41] On the contrary, Boyraz et al. found lower PLR levels in AS patients compared with controls. But in their study, the patients in the active phase excluded and the study group only consisted of patients who had been under anti-TNF therapy at least for 6 months. [42] There is no study in the literature where PLR levels were investigated in OA before. Nevertheless our results with higher levels of PLR in severe hip OA group are in concordance with the literature owing to the fact that OA is already accepted as a systemic inflammatory disorder.

MPV was also investigated widely in the past decade. It is frequently found to be decreased in the presence of active high grade inflammation; that is, active phase of RA, AS, ulcerative colitis and Chron disease [43–45] activation of systemic lupus erythematosus (SLE) arthritis [46] and active SLE. [47] Increased MPV levels were on the other hand mainly found in states of low grade inflammation such as: cellulitis, [48] idiopathic subjective tinnitus, [49] symptom/attack-free periods of familial Mediterranean fever patients [50] and irritable bowel syndrome, [51] obstructive sleep apnea syndrome. [52] Being a state of low grade systemic inflammation, OA, is also expected to be associated with higher levels of MPV and this is demonstrated in our study. In our study, higher levels of MPV was found in severe hip OA group and this is in concordance with the present literature as OA (even the severe form) is a low grade inflammatory condition. [41, 42]

The most important limitation of the present study is the cross-sectional design giving way to a chicken and egg situation and overshadowing the pathogenesis of elevated blood PLR and MPV levels in severe hip OA. Moreover, the use of a single blood sample does not allow assessment of the stability of blood levels over the time. So, longitudinal studies should be performed to evaluate the role of blood PLR and MPV in hip OA pathogenesis.

In conclusion, the results of the present study, for the first time, demonstrated that blood PLR and MPV can be used as basic indicators of radiographic severity of hip OA. Our results also support the part of low grade systemic inflammation in OA pathogenesis. According to the data from this study, MPV and PLR are useful in the clinical setting to assess the severity of hip OA.

### References

1. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthrosis is not osteoarthrosis!). Osteoarthr Cartil 2013;21:16–21.
2. Orlovsky EW, Kraus VB. The role of innate immunity in osteoarthritis: our first line of defense goes on the offensive. J Rheumatol 2015;42:363–71.
3. Cibulka MT, White DM, Woehrle J, et al. Hip pain and mobility deficits—hip osteoarthritis: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association. J Orthop Sports Phys Ther 2009;39:A1–25.
4. Bondeson J, Blom AK, Wannwright S, et al. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 2010;62:647–57.
5. Martel-Pelletier J, Alaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999;4:E694–703.
6. Katona G. Osteoarthritis—an inflammatory disease? Int J Tissue React 1983;5:645–61.
7. Legendre F, Dudiha J, Pujol JP, et al. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6 soluble IL-6R down-regulation of type II collagen, aggrecan core, and link protein transcription in articular chondrocytes association with a down-regulation of SOX9 expression. J Biol Chem 2003;278:2903–12.
8. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33–42.
9. Sun JM, Sun LZ, Liu J, et al. Serum interleukin-15 levels are associated with severity of pain in patients with knee osteoarthritis. Dis Markers 2013;31:203–6.
10. Erenti I, Haznedaroğlu IC, Kiraz S, et al. Cytokines affecting megakaryocytopenia in rheumatoid arthritis with thrombocytosis. Rheumatol Int 1996;16:5–8.
Tasoglu et al. Medicine (2017) 96:6

[11] Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009;7:1759–66.

[12] Rondina MT, Weyrich AS, Zimmermann GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013;112:1506–19.

[13] Debili N, Masse JM, Katz A, et al. Effects of the recombinant hematopoietic growth factor interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood 1993;82:84–95.

[14] Burstein SA, Downs T, Friese P, et al. Thrombocytopenia in normal and sublethally irradiated dogs: response to human interleukin-6. Blood 1992;80:420–8.

[15] Uslu AU, Küçük A, Şahin A, et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis 2015;18:731–5.

[16] Fu H, Qin B, Hu Z, et al. Neutrophil-to-platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin Lab 2015;61:269–73.

[17] Kim DS, Shin D, Lee MS, et al. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol 2016;43:305–10.

[18] Barth PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrolysis 1996;7:157–61.

[19] Thompson CB, Jakubowski JA, Quinn PG, et al. Platelet size as a determinant of platelet function. J Lab Clin Med 1983;101:205–13.

[20] Milovanovic M, Nilsson E, Jaremo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 2004;343:237–40.

[21] Kayahan H, Akarsu M, Ozcak MA, et al. Reticulated platelet levels in patients with ulcerative colitis. Int J Colorectal Dis 2007;22:1429–35.

[22] Canpolat F, Akpinar H, Eskioglu F. Mean platelet volume in psoriasis vulgaris and psoriatic arthritis. Clin Rheumatol 2010;29:325–8.

[23] Magen E, Mishal J, Zeldin Y, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci 2010;339:504–8.

[24] Yazici S, Yazici M, Erer B, et al. The platelet functions in patients with ankylosing spondylitis: anti-TNF-alpha therapy decreases the mean platelet volume and platelet mass. Platelets 2010;21:126–31.

[25] Yazici S, Yazici M, Erer B, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets 2010;21:122–5.

[26] Kim DA, Kim TY. Controversies over the interpretation of changes of mean platelet volume in rheumatoid arthritis. Platelets 2011;22:77–8.

[27] Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008;75:291–4.

[28] Makay B, Turkyilmaz Z, Unsal E. Mean platelet volume in children with familial Mediterranean fever. Clin Rheumatol 2009;28:975–8.

[29] Yuksel O, Helvacı K, Basar O, et al. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets 2009;20:277–81.

[30] Lidaka T, Muraki S, Akune T, et al. Prevalence of radiographic hip osteoarthritis and its association with hip pain in Japanese men and women: the ROAD study. Osteoarthritis Cartilage 2016;24:117–23.

[31] Kellgren JH, Lawrence RS. Radiological assessment of osteoarthritis. Ann Rheum Dis 1957;16:494–502.

[32] Cooper C, Egger P, Coggan D, et al. Generalized osteoarthritis in women: pattern of joint involvement and approaches to definition for epidemiological studies. J Rheumatol 1996;23:1938–42.

[33] Hanada M, Takahashi M, Furuhashi H, et al. Elevated erythrocyte sedimentation rate and high-sensitivity C-reactive protein in osteoarthritis of the knee: relationship with clinical findings and radiographic severity. Ann Clin Biochem 2016;53:548–53.

[34] Sanchez-Ramirez DC, van der Leeden M, van der Esch M, et al. Association of serum C-reactive protein and erythrocyte sedimentation rate with muscle strength in patients with knee osteoarthritis. Rheumatology (Oxford) 2013;52:727–32.

[35] Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013;13:350.

[36] Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466–72.

[37] Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216–22.

[38] Gary T, Pichler M, Belaj K, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS ONE 2013;8:e67688.

[39] Tasoglu I, Sert D, Colak N, et al. Neutrophil-lymphocyte ratio and the platelet-lymphocyte ratio predict the limb survival in critical limb ischemia. Clin Appl Thromb Hemost 2014;20:645–50.

[40] Boyraz I, Koç B, Boyacı A, et al. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treated with anti-TNF. Int J Clin Exp Med 2014;7:2912–5.

[41] Teleoglu I, Gürol G, Harman H, et al. Overlooked hematological markers of disease activity in rheumatoid arthritis. Int J Rheum Dis 2016;19:1078–82.

[42] Kapsoritakis AN, Koulourakis MI, Sfirdaki A, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776–81.

[43] Safak S, Uslu AU, Serdal K, et al. Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis. Afr Health Sci 2014;14:919–24.

[44] Delgado-Garcia G, Galarza-Delgado DÁ, Colunga-Pedraza I, et al. Mean platelet volume is decreased in adults with active lupus disease. Rev Bras Reumatol Engl Ed 2016;56:504–8.

[45] Ertürk A, Cure E, Cure MC, et al. The association between serum YKL-40 levels, mean platelet volume, and c-reactive protein in patients with cellulitis. Indian J Med Microbiol 2015;33:61–6.

[46] Sankaya Y, Bayraktar C, Karataş M, et al. Increased mean platelet volume in patients with idiopathic subjective tinnitus. Eur Arch Otorhinolaryngol 2016;273:3533–6.

[47] Özer S, Yilmaz R, Sonmezoglu E, et al. Simple markers for subclinical inflammation in patients with familial Mediterranean fever. Med Sci Monit 2015;21:298–303.

[48] Marzouk H, Lofty HM, Farag Y, et al. Mean platelet volume and splenomegaly as useful markers of subclinical activity in Egyptian children with familial Mediterranean fever: a cross-sectional study. Int J Chronic Dis 2015;2015:152616.

[49] Aktas G, Alcelik A, Tekce BK, et al. Red cell distribution width and mean platelet volume in patients with irritable bowel syndrome. Prz Gastroenterol 2014;9:163–5.

[50] Akyol S, Cortuk M, Baykan AO, et al. Mean platelet volume is associated with disease severity in patients with obstructive sleep apnea syndrome. Clinics (Sao Paulo) 2015;70:481–5.